Private Practice, Physical Medicine and Rehabilitation and Pain Management, Hilo and Honolulu, HI.
Department of Physical Medicine and Rehabilitation, University of Kansas, Kansas City, KS.
J Altern Complement Med. 2018 Dec;24(12):1189-1196. doi: 10.1089/acm.2018.0085. Epub 2018 Jun 8.
Chronic low-back pain (CLBP) participants in a prior controlled study reported short-term pain relief after caudal epidural injection of 5% dextrose (D5W). This study assessed whether repeated caudal epidural injections of D5W results in serial short-term diminution of CLBP and progressive long-term decrease in pain and disability. Prospective uncontrolled study. Outpatient pain clinic. Adults with CLBP with radiation to gluteal or leg areas. Caudal epidural injection of 10 mL of D5W (without anesthetic) every 2 weeks for four treatments and then as needed for 1 year. Numerical Rating Scale (NRS, pain, 0-10 points), Oswestry Disability Index (ODI, disability, %), and fraction of participants with ≥50% reduction in NRS score. Analysis by intention to treat. Participants ( = 32, 55 ± 9.8 years old, nine female) had moderate-to-severe CLBP (6.5 ± 1.2 NRS points) for 11.1 ± 10.8 years. They received 5.5 ± 2.9 caudal D5W injections through 12 months of follow-up. The data capture rate for analysis was 94% at 12 months for NRS and ODI outcome measures, with 6% carried forward by intention to treat. A consistent pattern of analgesia was demonstrated after D5W injection. Compared with baseline status, NRS and ODI scores improved by 3.4 ± 2.3 (52%) and 18.2 ± 16.4% (42%) points, respectively. The fraction of participants with 50% reduction in NRS-based pain was 21/32 (66%). Epidural D5W injection, in the absence of anesthetic, resulted in consistent postinjection analgesia and clinically significant improvement in pain and disability through 12 months for most participants. The consistent pattern postinjection analgesia suggests a potential sensorineural effect of dextrose on neurogenic pain.
先前的一项对照研究中,接受尾骨硬膜外注射 5% 葡萄糖(D5W)的慢性下腰痛(CLBP)患者报告短期疼痛缓解。本研究评估了重复尾骨硬膜外注射 D5W 是否会导致 CLBP 的短期连续减轻以及疼痛和残疾的长期逐渐减轻。前瞻性非对照研究。门诊疼痛诊所。有臀部或腿部放射痛的 CLBP 成人。每 2 周接受 10 mL D5W(无麻醉剂)的尾骨硬膜外注射,共进行 4 次治疗,然后根据需要在 1 年内进行。数字评分量表(NRS,疼痛,0-10 分),Oswestry 残疾指数(ODI,残疾,%),以及 NRS 评分至少降低 50%的参与者比例。意向治疗分析。参与者(n=32,55±9.8 岁,9 名女性)患有中重度 CLBP(NRS 评分 6.5±1.2),持续时间为 11.1±10.8 年。他们在 12 个月的随访中接受了 5.5±2.9 次尾骨 D5W 注射。NRS 和 ODI 结果测量的分析数据捕获率在 12 个月时为 94%,意向治疗中有 6%的数据向前结转。在 D5W 注射后表现出一致的镇痛模式。与基线状态相比,NRS 和 ODI 评分分别改善了 3.4±2.3(52%)和 18.2±16.4%(42%)。NRS 疼痛减轻 50%的参与者比例为 21/32(66%)。在没有麻醉剂的情况下,硬膜外 D5W 注射导致大多数参与者在 12 个月内持续注射后镇痛,并在疼痛和残疾方面有显著改善。注射后一致的镇痛模式表明葡萄糖对神经源性疼痛可能具有潜在的感觉神经效应。